Surgery in Nasal Polyp Patients: Outcome After a Minimum Observation of 10 Years.
In this study, we aim to estimate disease recurrence during a long-term follow-up, together with the investigation of possible predicting and/or influencing parameters. METHODS: Out of 196 patients operated for CRSwNP between 01/2000 and 01/2006, 133 patients had a follow-up of at least 10 years and could be included. The inflammatory profile at surgery was determined on nasal tissue and sinonasal secretions, and included analysis of eosinophils, eosinophilic-rich mucus (ERM) typically containing Charcot-Leyden crystals (CLC), and fungal hyphae (FH). During follow-up, recurrence, received treatments and comorbidities were collected. RESULTS: Out of the 133 included patients, local eosinophilia was present in 81% and ERM in 60%. Recurrence during follow-up was observed in 62%, and was associated with local eosinophilia and ERM (both p
ConclusionDifferent blood and tissue eosinophilia revealed distinct tissue inflammatory patterns in CRSwNP patients.
CONCLUSIONS: Chloroquine may be used for the treatment of patients with eosinophilic CRS. PMID: 32935491 [PubMed]
CONCLUSION: IL-22 was associated with type 2 inflammatory reactions in NP. The IL-22/IL-22Ra1 axis was enhanced and might be involved in type 2 inflammatory reactions via TSLP production in NP. PMID: 32935490 [PubMed]
Eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) exhibits a poorer outcome compared with non-eosinophilic chronic rhinosinusitis with nasal polyps (nonECRSwNP), so it is significant to identify ...
Conclusions: CRSwNP is fairly prevalent in the general population. Despite the significant efficacy of existing treatments, several unmet needs remain. The high burden of uncontrolled symptoms, frequent recurrence of nasal polyps after surgery, and long-term adverse effects of oral corticosteroids indicate that new therapies addressing these unmet needs should be developed. Although data on biologics from randomized controlled trials look promising, the efficacy of biologics in the real world has yet to be established.The SLR of the epidemiology and clinical burden of CRSwNP revealed key gaps in the literature. There was a...
AbstractPurpose of ReviewThis review highlights the expression and regulation of mucin in CRS and discusses its clinical implications.Recent FindingsChronic rhinosinusitis (CRS) is common chronic nasal disease; one of its main manifestations and important features is mucus overproduction. Mucin is the major component of mucus and plays a critical role in the pathophysiological changes in CRS. The phenotype of CRS affects the expression of various mucins, especially in nasal polyps (NP). Corticosteroids(CS), human neutrophil elastase (HNE), and transforming growth factor- β1 (TGF-β1) are closely related to the tis...
CONCLUSION: ILC2-mediated type 2 inflammation plays a crucial role in the pathogenesis of CRSwNP. Targeting upstream mediators responsible for activating ILC2 as well as downstream products these cells release may play an important role in modifying the inflammatory response and improving clinical outcomes in CRSwNP. PMID: 32781240 [PubMed - as supplied by publisher]
Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a chronic type 2 inflammatory response in the paranasal sinuses. Group 2 innate lymphoid cells (ILC2) are potent innate immune cells that contribute to type 2 inflammation by producing cytokines such as IL-4, IL-5 and IL-13. There is increasing evidence suggesting that ILC2 play an important role in CRSwNP pathogenesis.
Conclusion: Preoperative increased serum periostin and eosinophils in NPs are associated with the preventive effect of ESS for asthma exacerbations in CRS patients comorbid with asthma.Int Arch Allergy Immunol
We thank Lipworth et al1 for their correspondence about our recent publication,2 within which they acknowledge that studies with mepolizumab in chronic rhinosinusitis with nasal polyposis (CRSwNP) have shown benefit in reducing nasal polyp size.3,4 They, however, question the 22-item Sino-Nasal Outcome Test (SNOT-22) findings from the MUSCA5 study, a placebo-controlled study of mepolizumab in 551 participants with severe eosinophilic asthma of whom 19% (n = 105) reported nasal polyps at screening.